Cell and Gene Therapy Manufacturing Capacity
North America 2018

**ALDEVRON**
- **Capacity:** Four production trains across 32 rooms; 300 L single-use fermenter with expansion to 2,000 L
- **Spare capacity:** available 2018 and 2019
- **Clean rooms:** 17,000 square feet
- **Contact:** Tom Lynch, Vice President of Sales and Client Development
  - www.aldevron.com

**VGXI, INC.**
- **Capacity:** multiple production plants with small (40L) to large scale (500L) capability
- **Spare capacity:** contact for current availability
- **Clean rooms:** ISO Class 8 through Class 5
- **Contact:** Christy Franco, Manager, Business Development
  - www.vgxii.com

**HITACHI CHEMICAL ADVANCED THERAPEUTICS SOLUTIONS, LLC**
- **Capacity:** 50,500 square feet
- **Spare capacity:** expanding to add 49,700 additional square feet
- **Clean rooms:** 13
- **Contact:** Eric Powers, Director, Marketing and Communications
  - www.pctcelltherapy.com

**PARAGON BIOSERVICES, INC.**
- **Capacity:** microbial - 10 GMP campaigns per year, mammalian - 40 GMP campaigns per year, viral - 18 GMP campaigns per year
- **Clean rooms:** 9 GMP manufacturing suites
- **Contact:** Philip Wills, Chief Commercial Officer
  - www.paragonbioservices.com

**MERCK LIFE SCIENCE (MILLIPORESIGMA IN US & CANADA)**
- **Capacity:** open capacity varies depending on project scope
- **Spare capacity:** backlogs usually range from 6-12 months
- **Clean rooms:** 16
- **Contact:** Pat Barry, Sales Manager, Virus & Gene Therapy
  - www.bioreliance.com

**CCRM**
- **Capacity:** 14,000 sq. ft. GMP compliant space and 10,000 sq. ft. process development laboratories
- **Spare capacity:** contact for current availability
- **Clean rooms:** 10 class B clean rooms
- **Contact:** Steven Molinski, Manager, Contract Services
  - www.ccrm.ca

**PHACILITATE:**
- **Capacity:**
  - Lonza Pharma & Biotech: contact for current availability
  - Paragon Bioservices, Inc.: contact for current availability
  - Merck Life Science (MilliporeSigma in US & Canada): contact for current availability
  - CCRM: contact for current availability
  - Hitachi Chemical Advanced Therapeutics Solutions, LLC: contact for current availability
  - VGXI, Inc.: contact for current availability

---

*Key: USA, Canada*
I am excited to invite you to Fargo for the Breakthrough Symposium. Since founding Aldevron 20 years ago, our mission has been to make a meaningful difference in people's lives. We are fortunate to work with leading companies in gene and cell therapy, DNA vaccines, and antibody development, focusing on breakthroughs in treating and curing disease. We are honoured to have had a small part in the recent approval of transformative therapies and we look forward to what the next 20 years will bring.

Michael Chambers, CEO, Aldevron